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Half of all patients with inflammatory bowel disease show a significant reduction of their bone
mass during the course of their chronic inflammatory disease. In contrast to women with
postmenopausal osteoporosis these patients are much younger and a significant subgroup
develops vertebral fractures which are mostly asymptomatic.
The activity of the chronic inflammatory disease and the steroid treatment leads to bone loss
predominantly through the TNFα-driven osteoprotegerin system. Clinical useful genetic markers
to identify patients at risk for fractures have not been developed so far. Long-term clinical
remission leads in most patients to normalisation of the bone density. Patients with reduced bone
density should be substituted with calcium and vitamin D. Patients with vertebral fractures
should receive bisphosphonates.
© 2008 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.KEYWORDS
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Table 1 Bonedensity inpatientswith inflammatoryboweldisease
Normal bmd
TN−1
Osteopenia
Tb−1N−2,5
Osteoporosis
Tb−2,5
Author
Crohn's disease
42% 23% 35% von Tirpitz et al.
(1999)3
8% 55% 7% Ardizzone et al.
(2000)4
37% 50% 13% Siffledeen et al.
(2004)5
Ulcerative colitis
15% 67% 18% Ardizzone et al.
(2000)4
Proportion of patients with normal bone mineral density (bmd),
osteopenia Tb1and N−2.5 and osteoporosis in %.
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When measured by dual energy X-ray absorptiometry (DEXA)
bone density of the lumbar spine is significantly reduced in
the majority of patients with inflammatory bowel disease
(IBD) which are predominantly young patients between 20
and 40 years.
Most patients (40–50% of all patients) show a reduction of
bone density termed osteopenia with a T-score b1 and N2.5.
A T-score b2.5, which is the definition of osteoporosis, was
measured in 5–37% of IBD patients in several longitudinal
studies.1–5 Therefore we have in contrast to osteoporosis in
postmenopausal women a young population with IBD with a
substantial degree of bone loss compared to age and sex-
matched controls (see Table 1).
2. Crohn's disease (CD) versus ulcerative
colitis (UC)
As shown above loss of bone density is more pronounced in
Crohn's disease compared with ulcerative colitis. Until
recently this was attributed predominantly to malabsorption
caused by inflammation or surgical resection of small bowel
in Crohn's disease. The important influence of disease
activity on bone physiology and bone loss was not recognized
until recently. In recent cross-sectional studies the differ-
ence of bone loss between Crohn's disease and ulcerative
colitis is less pronounced or not significant (see Table 1).
In the early long-term studies looking at bone density over
time a steady ongoing bone loss was reported.6 This
phenomenon could not be reproduced in several following
papers.7,8 A landmark study on that subject was published
2003. Reffitt et al. have shown that patient's with Crohn's
disease and ulcerative colitis are able normalise their bone
density at the spine and at the hip when they were more than
3 years in stable remission of their inflammatory bowel
disease (see Fig. 1).9
3. Vertebral bone fractures
Reduction of bone density is not a disease and usually does
not cause lumbar pain in young patients. The important
question is if these patients have fractures of the lumbar
spine or an increased risk to develop fractures during the
course of their chronic inflammatory bowel disease.
In population-based studies using medical data bases an
increased incidence of vertebral fractures in young IBD
patients could not be consistently demonstrated.10,11 This is
not surprising sincemost patients are young and asymptomatic
even when coincidentally lumbar fractures are diagnosed.
Therefore the true incidence and prevalence of vertebral
fractures in young IBD patients does not show up in hospital
records or ICD statistics. In cross-sectional studies investigat-
ing prospectively cohorts of IBD patients a frequency of 15–22%
mostly asymptomatic vertebral fractures has been reported.
These studies have been performed in IBD-centers in Canada
(44/224 patients 20%),12 Germany (34/156 patients 22%)13 and
Europe and Israel (25/179 patients 14%).14
Surprisingly the incidence of vertebral fractures in these
patients does not correlate with the degree of bone loss. Twoof these 3 studies demonstrated a clear discordance between
the degree of bone loss and the prevalence of vertebral
fractures in patients with Crohn's disease. This leads to the
conclusion that bone mineral density (BMD) is only one of the
different risk factors leading to an increased fracture risk in
our patients. A prior vertebral fracture for instance is a strong
risk factor for subsequent fractures even when the bone
density is not diminished. There is a need for longitudinal
studies looking at fracture incidence over time and investi-
gating factors like bone histology and genetic markers to
develop a fracture risk index in this special patient group.
4. Etiology of osteoporosis in inflammatory
bowel disease
In osteologic textbooks patients with inflammatory bowel
diseases (IBD), rheumatoid arthritis (RA) and chronic ob-
structive pulmonary disease (COPD) and decreased BMD are
classified as steroid-induced osteoporosis. There is clear
evidence that long-term use of steroids decreases bone den-
sity (for review see15). But there is also compelling evidence
that there are subgroups of IBD patients which have received
long-term steroid therapy without significant bone loss and
steroid-naive patients who show a significant reduction of
lumbar bone density upon diagnosis of their inflammatory
bowel disease.16 This suggests that additional factors play a
significant role in the pathophysiology of bone loss in IBD.
First there is convincing evidence that the chronic
inflammatory disease itself leads to bone loss through the
TNFα- driven osteoprotegerin system. In some patients
secondary hyperparathyroidism due to malabsorption may
play a role but data regarding calcium, vitamin D and
parathormone levels are inconsistent.
Secondary amenorrhoea in young women with IBD due to
the activity of bowel disease leads to significant loss of bone
density and these patients should be substituted with
hormone in cooperation with a gynecologist.
If a decrease of testosterone due to disease activity plays
a similar role in young male patients with IBD is not
absolutely clear. Male secondary hypogonadism in IBD with
low androgen index and normal gonadotropins associated
with increased bone turnover was reported in about 6% of a
cohort of patients with Crohn's disease in England.17 In 111
Figure 1 Increase of bone mineral density in IBD patients with duration of remission: Mean Z-scores (SEM) at the femoral neck and
the lumbar spine of patients with Crohn's disease and with ulcerative colitis compared with duration of disease remission. *pb0.01,
**pb0.05 compared with active disease. Reprinted with permission of Wolters Kluwer.9
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testosterone, estradiol and SHBG levels were reported but
this was not significantly associated with low bone density
(Klaus et al. submitted for publication).
Furthermore the available data suggest that the indivi-
dual risk of osteoporosis and lumbar fracture in young
patients with IBDmight be significantly influenced by genetic
factors making patients more susceptible to long-term
steroid therapy or the chronic inflammation in their body.
5. Steroid-induced osteoporosis
As mentioned above chronic steroid use leads to loss of bone
density and an increased incidence of pathological fractures.
However in patients with chronic inflammatory diseases like
IBD and rheumatoid arthritis it is impossible to distinguish
between the impact of steroid use and the consequences of
chronic inflammation itself on bone density. Therefore there is
a variety of studies demonstrating dose-dependent effects of
corticosteroids on bone density in patients with IBD5,8 whereas
other studies did not show significant associations.2,18
6. Osteoprotegerin/RANK-L
The discovery and characterization of the soluble receptor
activator of NF-kB ligand (sRANKL) and its receptor antagonist
osteoprotegerin (OPG) have led to a new molecular concept
of the cell biology of osteoclasts and of bone metabolism.
RANKL is expressed on the cell surface of osteoblasts.
Binding to RANK receptor expressed on osteoclast precursors
leads to osteoclast differentiation, activation and bone lossthrough the expanded, activated osteoclasts. The interac-
tion of RANK and RANK-ligand is inhibited by the internal
receptor antagonist OPG (osteoprotegerin). Systemic gluco-
corticoids inhibit OPG production, lead to an increase of
sRANKL gene expression in osteoblasts, and again stimulate
differentiation, fusion and activation of osteoclasts. Even
after short-term steroid therapy significant inhibition of OPG
and induction of RANK-L could be demonstrated within
weeks.19 Furthermore OPG expression is also directly
inhibited in flares of the disease by several inflammatory
cytokines (interleukin-1 and interleukin-6, tumour necrosis
factor-α) that are released in response to chronic inflamma-
tory bowel disease (for review see20).
In one recent study with IBD patients with reduce bone
density OPG levels were shown to be constantly elevated in the
serum of patients with Crohn's disease and ulcerative colitis
whereas sRANKLwere not significantly elevated in IBD patients
compared with controls. This was interpreted as the chronic
homeostatic response of the system to reverse osteopenia.21
It is therefore necessary to perform longitudinal studies in
patients with chronic inflammatory bowel disease measuring
over time OPG/RANKL and BMD to validate the concept of
bone loss by alterations of the osteoprotegerin system.
The concept of the influence of active disease on bone
loss in IBD is indirectly supported by following studies:
1) Patients with Crohn's disease and ulcerative colitis which
show reduced bone density during the active phase of
their disease gradually improve their bone density when
they are 1–3 years or more than 3 years in remission. After
3 years in remission most patients have “normalised”
their bone density without specific therapy (see Fig. 1).9
205Osteoporosis in inflammatory bowel disease2) Treatment with azathioprine in patient's with chronic
active disease leading to diminished disease activity
significantly improves bone density.22
3) Treatment with TNF-α antibodies induced bone forma-
tion23 and together with bisphosphonates significantly
increased bone density (6.7% versus 4.7%) compared to
the treatment with bisphosphonates alone.24
Furthermore it has been shown that glucocorticoids
increase the expression of RANK-L and decease the expres-
sion of OPG.25 Recently it has been demonstrated that
steroids indirectly suppress the promoting activity of the
wingless (wnt) signalling system on osteoblastogenesis.26
7. Secondary hyperparathyroidism
Osteomalacia due to secondary hyperparathyroidism due to
malabsorption is the hallmark of osteopenia in celiac
disease. Prolonged bone loss in celiac disease leads pre-
dominantly to peripheral and seldom to vertebral fractures
like in patients with IBD.
Reduction of malabsorption by adhering to a gluten-free
diet leads in the majority of patients to a normalisation of
bone density.27 In patient's with Crohn's disease and
malabsorption due to disease activity and/or extensive
resections of the small bowel elevated parathormone levels
can be measured. In these cases a mixture of osteomalacia
and osteoporosis can be diagnosed.
In most studies looking for secondary hyperparathyroid-
ism in patients with IBD consistent elevation of parathor-
mone due to decreased calcium levels could not be
demonstrated.28–30 Therefore secondary hyperparathyroid-
ism seems to play a minor role in the pathogenesis of
osteoporosis in inflammatory bowel disease.
8. Genetic factors
As mentioned above there are patients with high and chronic
disease activity which have been treated with large doses of
steroids during their disease course and show a normal boneTable 2 Treatment of patients with inflammatory bowel disease
bisphosphonates
Drug Ca/vitamin D Increase BMD spine 1
Pamidronate 30 mg
i.v. every 3 months
1000 mg Ca
400 IU Vit. D
0.51 (T-score)
Pamidronate 30 mg
i.v. every 3 months
500 mg Ca
400 IU Vit. D
2.6%
1.6% (Ca/Vit. D)
Risedronate 5 mg p.o. 600 mg Ca 2.0%
1.9% (Ca)
Risedronate 35 mg
p.o. per week
Etidronate 400 mg
p.o. cyclic
500 mg Ca
400 IU Vit. D
3.7%
3.7% (Ca/Vit. D)
Alendronate 10 mg p.o. 1000 mg Ca
400 IU Vit. D
4.6%
−0.9% (Ca/Vit. D)
Ibandronate 1 mg
i.v. every 3 months or
sodium fluoride 25 mg
b.d. p.o. cyclic
800 mg Ca
1000 IU Vit. D
5.4%
2.6% (Ca/Vit. D)
5.7% (NaF)density. This points out that individual “protective” genetic
factors play a significant role. On the other hand some
patients show a severely reduced bone density at the time of
diagnosis without any steroid therapy. In these patients
genetic factors seem to have a dominant role on bone loss
during their chronic disease.
Several genetic markers have been investigated in order
to identify subgroups of patients on which the attention
should be focused.
In postmenopausal osteoporosis a plethora of gene
polymorphism like e.g. the vitamin D receptor gene31 the
estrogen receptor gene32 has been inversely associated with
low bone density (for review see33).
In patients with inflammatory bowel diseases significant
associationswith lowbonedensity havebeen reported for IL-6,
IL1ra and COL1A1-SNP's.34–36 No significant associations with
low bone density have been reported with SNP's of the vitamin
D receptor in patients with Crohn's disease.37
Due to the importance of the osteoprotegerin system in
the regulation of bone density during inflammatory diseases
polymorphisms in these genes have been investigated to find
clinically relevant genetic markers for bone loss. So far
conflicting results in patients with postmenopausal osteo-
porosis concerning SNP's in the osteoprotegerin system genes
have been reported. A SNP in the OPG gene and the RANK-L
gene was associated with low density in Korean and Danish
postmenopausal women38,39 but not in elderly Swedish
women.40 Surprisingly mutations in the OPG gene are
strongly associated with coronary artery disease41 which
leads to the hypothesis that bone resorption in these patients
leads to increased vascular calcification.42 Studies looking at
SNP's in the osteoprotegerin systems in patients with chronic
inflammatory diseases looking at associations with bone
density have not been reported so far.
9. Therapy of osteoporosis in inflammatory
bowel disease
How should patients with inflammatory bowel diseases be
treated when a significant decrease of bone density has beenand decreased bone mineral density (bmd) with different
year Patients Author
49 Stokkers et al. (2006)48
74
(37/37)
Bartram et al. (2003)45
48
(23/25)
Henderson et al. (2006)49
90 all female per week
postmenopausal
Palomba et al. (2005)50
143
(72/71)
Siffledeen et al. (2005)47
32
(17/15)
Haderslev et al. (2000)51
84 von Tirpitz et al. (2003)46
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osteoporosis or patients with senile osteoporosis used as the
base for therapeutic guidelines in patients with IBD? Most
studies have investigated the effect of calcium/vitamin D
and several bisphosphonates on bone density during 12 to
24 months of therapy.
10. Calcium and vitamin D
In one of the first studies in patient's with Crohn's disease
treatment with 1000 IU vitamin D/day for one year leads to a
significant increase of bone density.43 One study used a food
questionnaire to estimate retrospectively calcium und vitamin
D intake inwomenwith inflammatory bowel disease. Since the
variation of calcium and vitamin D intake was considerable no
clear results regarding the effect on bone density could be
drawn.44 In prospective, controlled bisphosphonate studies
where placebo groups received only calcium and vitamin D the
increase of lumbar bone density after one year was 1.6%45 and
2.6%.46 In one long-term study therapy with calcium/vitamin D
increased bone density at the spine after 2 years by 3.7%.47
11. Bisphosphonates
Several studies investigated the effect of oral or intrave-
nously given bisphosphonates over 12 to 24 months on bone
density in patients with inflammatory bowel disease.
Therapy with pamidronate,45,48 risedronate,49,50 alen-
dronate,51 etidronate47 and ibandronate46 significantly
increased bone density at the spine after one or two years
of therapy (Table 2).
In none of these studies an effect of bisphosphonate
therapy on the incidence of vertebral fractures could be
demonstrated. In one study, which has been so far only
reported in abstract form 178 patients were treated over
3.5 years with either calcium and vitamin D alone or in
combination with cyclic sodium fluoride or intermittent i.v.
ibandronate. In all groups BMD at the spine increased steadily
and significantly over time but no significant reduction of
vertebral fracture rate could be reported (von Tirpitz, in
preparation for publication).
12. Conclusions and guidelines for therapy
Data from studies with osteoporosis in postmenopausal
women or in senile osteoporosis cannot be extrapolated for
patients with osteoporosis in inflammatory bowel disease
since these patients are much younger and the pathophysiol-
ogy of bone loss is largely different. Therefore controlled
studies in IBD patients are necessary to establish valid
evidence-based therapeutic recommendations.
Most guidelines propose substitution with calcium (500–
1000 mg/die) and vitamin D (800 IU/die) in patients with
inflammatory bowel disease and reduced bone density.
Additionally every patient on steroid therapy should be
substituted with calcium and vitamin D.52
Since the effectiveness of bisphosphonates in primary
prevention of vertebral fractures in IBD patients with
significantly diminished bone density has not been demon-
strated yet it is not generally recommended. In IBD patientswith low BMD and established low-impact fractures treat-
ment with bisphosphonates is indicated.
There are no data concerning treatment of IBD patients
with emerging therapies like teriparatide, strontium rane-
late or recombinant OPG. Therefore these treatment
modalities should be evaluated in controlled studies in IBD
patients before they can be generally recommended.
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